GILD · Gilead Sciences, Inc.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $129.45 to $130.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $122.79 to $123.785. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $123.81 to $124.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $131.71 to $132.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $132.71 to $133.295. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $130.66 to $131.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $130.67 to $131.505. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $129.66 to $130.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $132.74 to $132.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $131.71 to $132.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

100% of the restricted stock units vested immediately upon the grant date of April 30, 2026.

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.